

ORIGINAL ARTICLE

Detection of *vacA*, *cagA* and *iceA* genes of *H. pylori* in dyspeptic patients and their association with clinical data and histopathological abnormalities

¹Enas Sh. Khater*, ²AbdAlazim A. AlFaki

¹Department of Microbiology and Immunology, Faculty of Medicine, Benha University, Egypt; Microbiology Laboratory, Al-quwayiyah General Hospital, Riyadh, KSA.

²Department of Internal Medicine, Al Quwayiyah General Hospital, Saudi Arabia

ABSTRACT

Key words:

Helicobacter pylori, Peptic ulcer, Virulence factors, Gastritis

*Corresponding Author:

Enas Shaban Hassan Khater
Assistant Professor
Microbiology and immunology.
Faculty of medicine Banha
University
01015570016
drenaskhater@yahoo.com

Background: Despite that most *H. pylori* infections are asymptomatic, some can develop major diseases like peptic ulcer and adenocarcinoma of stomach. **Objectives:** This study aimed to study the prevalence of *H. pylori* using real time PCR. Furthermore, detection of the *cagA*, *iceA1*, *iceA2*, *vacA* virulence genes and their relationship to clinical and histopathological alterations. **Methods:** Two gastric specimens were taken from every patient endoscopically, one of them was sent to histopathological analysis and the second biopsy was minced into tiny parts for real time PCR assay. **Results:** The results revealed that the prevalence of *H. pylori* was 66.67%. Thirty one (50%) of the studied strains harbored *cagA* gene. *IceA* gene was positive in 41.94%. The *vacA* gene was detected in all 62 (100%) samples. Many *vacA* gene subtypes were detected, the highest found was *s1as1bm* 20.97%. A significant association was detected between the endoscopic features and *vacA* presence. The subtypes of *vacA*: *s2*, *m2*, *s1a1b*, *s1as1bm2*, were related to gastritis, while *s1a*, *s1b*, *m1* were related to duodenal and stomach ulcers. No significant association between *cagA* presence and endoscopic or histopathological findings, but more than 66% of duodenal ulcers had positive *cagA* gene. There was a significant association between the *iceA1* and *iceA2* genes presence with gastritis and gastric ulcer. **Conclusion** the study of *H. pylori* virulence factors allows the clinician to identify high-risk patients caused by *H. pylori* infections.

INTRODUCTION

Helicobacter pylori (*H. pylori*) is a Gram-negative pathogen that has a significant association with gastrointestinal disorders development including peptic ulcers, gastric cancer, MALT lymphoma^{1,2}. There was an association between gastric cancer and peptic ulcer diseases with more than a million deaths worldwide each year, making it a major public health concern^{3,4}. To diagnose *H. pylori*, a lot of procedures are utilized, that can be classified as invasive or non-invasive. The invasive procedures which are the gold standard include microbiological culture, rapid urease test (RUT) and biopsy-based PCR. Noninvasive techniques such as stool antigen testing (SAT), urea breath tests (UBT), and serological tests are well documented and validated⁵.

Biopsy-based approaches may suffer from being invasive procedures, bacterial low concentration in fragments, decreased culture sensitivity and error of sampling⁶. Similarly, the accuracy of immunological tests is a point of controversy. Stool antigen assays are inaccurate due to administration of antibiotics, proton pump inhibitor and presence of upper GIT hemorrhage.

Therefore, molecular techniques such as PCR have recently improved the diagnostic procedures which detect *H. pylori*. It also detects the genetic alterations in the bacteria to understand drug resistance traits⁶ and presence of pathogen co-infection in gastric disorders⁷. The molecular techniques also help in comparative studies between conventional methods like microscopy plus rapid urease test with PCR in low-income regions for proper diagnosis and treatment⁸.

The cytotoxin-associated gene A (*cagA*) is found in about half of *H. pylori* strains and is a part of the cytotoxin-associated gene pathogenicity island (*cagPAI*) which is essential for the secretion system type IV. Genotypes of *H. pylori* that are *cagA*-positive cause mucosal irritation and the generation of interleukin-8 (IL-8) and are linked to etiology of stomach malignancy⁹. *CagA* positive has been identified in practically all *H. pylori* isolates recovered from affected individuals in Asian nations¹⁰.

The vacuolating cytotoxin gene (*vacA*) is presented in most of *H. pylori* isolates and codes for vacuolating cytotoxin. It plays a role in the pathophysiology by damaging the epithelial cell of the stomach¹¹. The *vacA* gene has two parts: a signal region (*s1/s2*) and a middle

region (*m1/m2*). *VacA* allelic variants in various regions, and their hazardous action, have been documented in prior studies¹². Another virulence *H. pylori* gene is *iceA* (triggered by epithelial contact) that detected in two allelic forms *IceA1* and *iceA2*, with *iceA1* being extensively linked to peptic ulcer^{13,14}.

This study aimed to study the prevalence of *H. pylori* using real time PCR. Furthermore, detection of the *cagA*, *iceA1*, *iceA2*, *vacA* virulence genes and their relationship to clinical and histopathological alterations.

METHODOLOGY

Biopsies Collection:

Gastric specimens were collected from 102 cases who had dyspeptic symptom who visited Gastroenterology Clinic in Al Quwayiyah General Hospital, Riyadh, Saudi Arabia. the study start from May 2021 to May 2022 using upper GIT endoscopy, fiberoptic endoscope (EG 530 WR, Fujinon), 2 antral biopsies were taken from every patient. Cases that were excluded from this work were the patients who had taken non-steroidal anti-inflammatory medications, antibiotics or antiacids within the last four weeks before starting the study.

Histopathology examination:

A biopsy from every patient was sent to the regional laboratory, Riyadh to check for histopathological abnormalities caused by the *H. pylori* infection. All specimens were fixed overnight using 10% formalin, handled and set in paraffin. Tissue slices which were 4 mm in thickness were obtained then stained using a Giemsa stain (Sheedhan's modified method) and standard hematoxylin and eosin¹⁵ before being analyzed and graded using Sydney's categorization¹⁶.

DNA extraction

It was done by the DNeasy tissue and blood kit (Qiagen, Hilden, Germany) as per the manufacturer guidelines after mincing the specimens into tiny parts with sterile scalpels.

H. Pylori Detection by Real time (RT) PCR

All DNA samples were collected from the 102 gastric specimens and were subjected to amplification by real-time PCR using the kit of *H. pylori* genesig Quantification ((PrimerDesign Ltd. Southampton, U. K), that was based on primer-probe and targets of the *H. pylori* *rpoB* gene. The assays were done in volumes of 20 μ l which included 10 μ l of "oasig™ 2 \times qPCRMastermix" (PrimerDesign Ltd.), 1 μ l specific primer/probe of *H. pylori*, 1 μ l primer/probe mix as an internal control, 3 μ l of the specimen extracted DNA, 2 μ l of DNA internal control, a volume of 20 μ l was made up by putting RNase/DNase free water. The PCR reactions were done using Smart Cyclor (Cepheid, Italy). During each PCR run the positive control which was DNA of *H. pylori* provided in the kit was added to the reaction and DNase/ RNase free water was also added to the reaction as a negative control. The PCR cycles were 50 cycles of denaturation at 95°C for 10 s and annealing and extension at 60°C for 60 s.¹⁷

VacA, *cagA* and *iceA* virulence genes detection

Real time PCR for *H. pylori* was used for *vacA*, *cagA* and *iceA* virulence genes detection. Every gene was identified using a unique PCR with its own primer pair. The amplification processes were done in a volume of 50 μ l using reaction buffer. 5 μ l of 10 x PCR buffer enriched with MgCl₂ (15 mM MgCl₂, 50 mM KCl, 10 mM Tris-HCl), DNT mix (0.2 mM of dCT, dATP, dTTP, and dGTP) (Roche, Germany), 2.5 U of Fast Start *Taq* DNA polymerase (Roche, Germany), 0.4 μ M of every primer, 5 μ l of DNA template, RNase and DNase free water were added up to a volume of 50 μ l. The PCR cycling was 30 cycles for 10 min of 94 °C then 55 °C for 2 min and 72 °C for 2 min, later the extension step, 72 °C for 10 min. Separation of the PCR products was done using Tris-acetate-EDTA buffer and 1.5% agarose gels (Promega, Madison, USA) then staining by ethidium bromide and visualization of bands using a U.V. transilluminator¹⁴.

Table 1: Primers used for *cagA*, *vacA* and *iceA* virulence genes detection by Real time PCR

Primers	Sequence	Product size
<i>CagA</i> -F	GATAACAGGCAAGCTTTTGAGG	349
<i>CagA</i> -R	CTGCAAAAGATTGTTTGGCAGA	
<i>Sl</i> a-F	TCTYGCTTTAGTAGGAGC	212
<i>Sl</i> a-R	CTGCTTGAATGCGCCAAAC	
<i>Sl</i> b-F	AGCGCCATACCGCAAGAG	187
<i>Sl</i> b-R	CTGCTTGAATGCGCCAAAC	
<i>Sl</i> c-F	CTYGCTTTAGTRGGGYTA	213
<i>Sl</i> c-R	CTGCTTGAATGCGCCAAAC	
<i>S</i> 2-F	GCTAACACCCAAATGATCC	199
<i>S</i> 2-R	CTGCTTGAATGCGCCAAAC	
<i>M</i> 1-F	GGT AAAATGCGGTCATGG	290
<i>M</i> 1-R	CCATTGGTACCTGTAGAAAC	
<i>M</i> 2-F	GGAGCCCCAGGAAACATTG	352
<i>M</i> 2-R	CATAACTAGCGCCTTGCAC	
<i>IceA</i> 1-F	GTGTTTTTAACCAAAGTATC	247
<i>IceA</i> 1-R	CTATAGCCASTCTTTGCA	
<i>IceA</i> 2-F	GTTGGGTATATCACAATTTAT	229/334
<i>IceA</i> 2-R	TTRCCCTATTTTCTAGTAGGT	
<i>Cag</i> empty site Luni1-F	ACATTTTGGCTAAATAAACGCTG	550
<i>Cag</i> empty site Luni1-R	GGTTGCACGCATTTTCCCTTAATC	

RESULTS

Statistical analysis

The data was interpreted by the use of SPSS version 20 (IBM Corp., NY, USA). Descriptive and inferential statistics were used in the statistical tests. The Chi Square/Fisher Exact test was used to determine whether proportions differences were significant. To illustrate statistical significance, P-values less than 0.05 was considered significant.

The *H. pylori* was detected in 68 (66.67%) samples of 102 collected biopsies using R.T PCR, Table 2. showed that only 62 (91.18%) of them harbored virulence genes. It was found that out of 62 virulent *H. pylori* strains, 31(50%) were *cagA* positive, 30 (48.39%) were *cagA* negative and 1(1.61%) was mixed. *IceA* gene was detected in 26 (41.94%) while it was negative in 21(33.87%) and mixed *iceA*1 and *iceA*2 in 2(3.23%). *VacA* gene was detected in the 62 virulent strains (100%). Many *vacA* gene subtypes were detected, the highest found was *slas1bm* 13 (20.97%) strains followed by *m*2, *s*2 and *sl*a1*b* alleles which were found in 11 (17.74%) strains for each subtype.

Table 2: Genes distribution in *H.pylori* strains among studied patients

Genes identified		No of isolates = 62	Percentage
<i>CagA</i>	Positive	31	50%
	Negative	30	48.39%
	Mixed	1	1.61%
<i>Vac A</i>	<i>Sl</i> a	6	9.68%
	<i>Sl</i> b	8	12.90%
	<i>S</i> 2	11	17.74%
	<i>M</i> 1	1	1.61%
	<i>M</i> 2	11	17.74%
	<i>Sl</i> a1 <i>b</i>	11	17.74%
	<i>Sl</i> as1 <i>bm</i> 1	1	1.61%
	<i>Sl</i> as1 <i>bm</i> 2	13	20.97%
<i>IceA</i>	<i>IceA</i> 1	26	41.94%
	<i>IceA</i> 2	21	33.87%
	Mixed	2	3.23%
	Negative	13	20.97%

Table 3. showed the correlation between various *H. pylori* genotypes with age and sex. There was no significant statistical difference between the *cagA*, *vacA* and *iceA* genes presence and gender. Although, *m2* subtype of *vacA* was found to be increased in females, 7(63.64%) than males, 4(36.36%), while mixed *iceA* was only found in males. No significant differences were

observed between *cagA*, *vacA* and *iceA* genotypes and the various groups of age. However, *m2* was high 6 (54.55%) in the patients aged from 18 to 29 years, while it was decreased 1(9.09%) among patients aged from 30 to 49 years and 3(27.27%) in patients aged more than 50 years old.

Table (3): Correlation between various *H. pylori* genotypes with age and sex

Genes		Sex		P	Age				Total	P
		Male=32	Female=30		18-29	30-40	40-49	50+		
<i>CagA</i>	Positive	15(48.38%)	16(51.61%)	0.698	11(35.48%)	6(19.35%)	6(19.35%)	8(25.80%)	31	0.229
	Negative	16(53.33%)	14(46.67%)		12(40.00%)	5(16.67%)	7(23.33%)	6(20.00%)	30	
	Mixed	1(100.00%)	0(0%)		0(0%)	1(100%)	0(0%)	0(0%)	0(0%)	
<i>VacA</i>	<i>S1a</i>	3(50.00%)	3(50.00%)	0.509	2(33.33%)	3(50.00%)	1(16.67%)	0(0%)	6	0.298
	<i>S1b</i>	5(62.50%)	3(37.50%)		2(25.00%)	1(12.50%)	3(37.50%)	2(25.00%)	8	
	<i>S2</i>	6(54.54%)	5(45.45%)		4(36.36%)	3(27.27%)	3(27.27%)	1(9.09%)	11	
	<i>M1</i>	0(0%)	1(100%)		0(0%)	1(100%)	0(0%)	0(0%)	1	
	<i>M2</i>	4(36.36%)	7(63.64%)		6(54.55%)	1(9.09%)	1(9.09%)	3(27.27%)	11	
	<i>S1a1b</i>	7(63.63%)	4(36.36%)		1(9.09%)	3(27.27%)	4(36.36%)	3(27.27%)	11	
	<i>S1a1bm1</i>	0(0%)	1(100%)		0(0%)	0(0%)	0(0%)	1(100%)	1	
	<i>S1a1bm2</i>	7(53.84%)	6(46.15%)		2(15.38%)	4(30.77%)	2(15.38%)	5(38.46%)	13	
<i>IceA</i>	<i>IceA1</i>	13(50.00%)	13(50.00%)	0.531	8(30.77%)	8(30.77%)	6(23.08%)	4(15.38%)	26	0.569
	<i>IceA2</i>	10(47.62%)	11(52.38%)		9(42.86%)	2(9.52%)	5(23.81%)	5(23.81%)	21	
	Mixed	2(100%)	0(0%)		1(50.00%)	0(0%)	1(50.00%)	0(0%)	2	
	Negative	7(53.85%)	6(46.15%)		5(38.46%)	2(15.38%)	3(23.08%)	3(23.08%)	13	

Table 4. showed the correlation between *vacA* with endoscopic features and histopathological findings. A significant association, (*p* value, 0.001) was found between the endoscopic features and *vacA* gene presence. The subtypes of *vacA*: (*s2*, *m2*, *s1a1b*, *s1a1bm2*), were related to gastritis, while, subtypes *s1a*, *s1b*, *m1* were related to duodenal and gastric ulcers. No statistical significance (*p* value of 0.229) was

detected between genotypes of *vacA* and histopathological alterations, although, *vacA* subtypes: (*s2*, *s1a1b*, *s1a1bm2*) were increased in severe chronic active gastritis. The *vacA* subtypes *S1a* and *S1b* were associated mainly with severe gastritis, while the subtype *vacA*, *m2* and *S1a1bm2* was highly associated with moderate active gastritis *S1a1bm1*

Table 4: Correlation between *VacA* with endoscopic feature and histopathological findings

	<i>VacA</i>								Total	P
	<i>S1a</i>	<i>S1b</i>	<i>S2</i>	<i>M1</i>	<i>M2</i>	<i>S1a1b</i>	<i>S1a1bm1</i>	<i>S1a1bm2</i>		
Endoscopic feature										0.001
Normal	1(11.11%)	2(22.22%)	1(11.11%)	0(0%)	2(22.22%)	1(11.11%)	0(0%)	2(22.22%)	9	
Gastritis	2(4.44%)	2(4.44%)	10(22.22%)	0(0%)	9(15.56%)	10(17.78%)	1(2.22%)	11(20%)	45	
Gastric ulcer	2(40%)	3(60%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	5	
Duodenal ulcer	1(33.33%)	1(33.33%)	0(0%)	1(33.33%)	0(0%)	0(0%)	0(0%)	0(0%)	3	
Histological findings										0.229
Chronic gastritis										
Mild	0(0%)	2(28.57%)	2(20.75%)	0(0%)	2(20.75%)	1(14.28%)	0(0%)	0(0%)	7	
Moderate	2(18.18%)	0(0%)	1(9.09%)	0(0%)	3(27.27%)	2(18.18%)	0(0%)	3(27.27%)	11	
Sever	1(25.00%)	1(25.00%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	2(50.00%)	4	
Chronic active gastritis	3(7.50%)	5(12.50%)	8(20.00%)	1(2.50%)	6(15.00%)	8(20.00%)	1(2.50%)	8(20.00%)	40	

Table 5 showed non significant differences between *cagA* presence and endoscopical or histopathological changes, but more than 66% of duodenal ulcers had positive *cagA*. There was significant association between *iceA1* and *iceA2* genes and gastritis and gastric

ulcer as *p* value was 0.027. There was an association between *iceA1* and *iceA2* with chronic active gastritis, 40% and 45% respectively, while the *iceA* negative cases were associated with chronic active gastritis in (15%) only.

Table (5): Correlation between *cagA* and *iceA* with endoscopic feature and histopathological findings

	<i>CagA</i>			p	<i>IceA</i>				Total	p
	positive	negative	mixed		Ice A1	IceA2	Mixed	Negative		
Endoscopic feature				0.479					62	0.027
Normal	4(44.44%)	5(55.56%)	0(0%)		2(22.22%)	3(33.33%)	0(0%)	4(44.44%)		
Gastritis	22(48.88%)	22(48.88%)	1(2.22%)		21(46.66%)	15(33.33%)	2(4.44%)	7(15.56%)		
Gastric ulcer	2(40.00%)	3(60.00%)	0(0%)		3(60.00%)	1(20.00%)	0(0%)	0(0%)		
Duodenal ulcer	2(66.67%)	1(33.33%)	0(0%)		1(33.33%)	1(33.33%)	0(0%)	1(33.33%)		
Histological findings				0.698					62	0.481
Chronic gastritis										
Mild	4(57.14%)	3(42.86%)	0(0%)		4(57.14%)	3(42.86%)	0(0%)	0(0%)		
Moderate	4(45.45%)	7(63.63%)	0(0%)		5(45.45%)	0(0%)	0(0%)	6(54.54%)		
Sever	3(75%)	0(0%)	1(25%)		1(25%)	0(0%)	2(50%)	1(25%)		
Chronic active gastritis	20(50%)	20(50%)	0(0%)	16(40%)	18(45%)	0(0%)	6(15%)			
Total	31	30	1		26	21	2	13		

Fig.(1): showed Real time PCR amplified *cagA* gene products (349 bp), *iceA1* gene (247 bp) and *iceA2* gene (229 or 334 bp).




Fig. 1: showed PCR-based genotyping amplified products of (1) *cagA* gene (349 bp).Lanes; M; DNA ladder (100 bp). *cagA* positive observed in Lanes 1, 2, 3, 5, 7, 9, 11, and 15 (2) *iceA1* gene (247 bp). Lanes; M; DNA marker (100 bp), *iceA1* positive was seen in Lanes 1, 2, 3, 4, 5, 7, 8, 9, 11, 13, 14 and 15. (3) *iceA2* gene (229 or 334 bp). Lanes; M; 100 bp molecular DNA marker, Lanes 1, 4, 6, 10, 11, and 12 are *iceA2* positive. The PCR products in lanes 1, 6 and 12 are of 334 bp size, while lanes 4, 10 and 11 have 229 bp PCR products

Fig. (2): showed PCR-based genotyping amplified products of *vacA* gene




Fig. 2: showed PCR-based genotyping amplified products of *vacA* gene .(1) PCR products of *vacA s1a* gene (212 bp). Lanes; M; 100 bp molecular DNA marker, positive *vacAs1a* gene was found in Lanes 4, 5, 8, 9, and 10 (2) PCR products of *vacA s1b* gene (187 bp). Lanes; M; 100 bp molecular DNA marker, *vacAs1b* gene was detected in Lanes 2, 5, 7, 8 and 9. (3) products of *vacA m2* gene (352 bp). Lanes; M; 100 bp molecular DNA marker , *vacAm2* gene detected in Lanes 1, 2, 3, 5, 6, 7 and 10 .

DISCUSSION

H. pylori colonizes the stomach and causes inflammatory response in the mucosa of stomach known as "gastritis." Without antibiotic therapy, such a disease can last for decades. Gastritis is the earliest visible changes in a step-wise process of histopathological changes which might proceed to gastric tumor¹⁸

In this work *H. pylori* prevalence was 66.67% as tested by real time PCR. This result matched with another study conducted in Al Kharj region in Riyadh by Alanazi et al.¹⁹ who reported *H. pylori* presence among the involved cases was (62.2%). In several researches all-over the world in United States, Brazil and China, the *H. pylori* prevalence between dyspeptic patients was 28.9%, 57%, and 84% respectively Ramis et al.²⁰ Another study by Aleid et al.²¹ reported that the *H. pylori* prevalence in studied cases in Riyadh was 39%. This data was lower than this report. This difference among Saudi Arabia regions was due to

several reasons, such as personal hygiene, healthcare system, and socioeconomic status²². In this study *CagA* positive were 50%, while 48.39% were negative for *cagA* and 1.61% was mixed. Similar results were obtained by Akeel et al.¹⁷ who detected *cagA* in 49.2% of *H. pylori* strains . The results also were similar to the studies by Momenah et al.²³, Marie et al.¹⁰., Kadi et al.¹⁴ in Saudi Arabia, they found *cagA* prevalences were 52.4%, 62% and 81.8% respectively. In Egypt, Abu Taleb et al.²⁴ reported the prevalence of *cagA* was about 57% in their studied group.

In our study *iceA* gene was harboured in 41.94% of strains, while it was negative in 33.87% and mixed *iceA1* and *iceA2* in 3.23%. Akeel et al.¹⁷ also reported that about 42 % of *Helicobacter pylori* had *iceA1* and 32.8% had *iceA2*. Similar findings also obtained with Sedaghat et al.²⁵. Abu Taleb et al.²⁴ who found the prevalence *iceA* gene in 48.6% and 46.29% cases respectively.

In the present work, *vacA* was revealed in the 62 (100%) virulent *H. pylori* isolates. Many *vacA* gene subtypes were detected, the highest found was *s1as1bm2* 20.97%, then *m2*, *s2* and *s1a1b* alleles which were detected in 17.74% strains for every subtype. The same findings were revealed by El Khadir et al.²⁶ who reported that 99% of *H. pylori* isolates in Morocco had *vacA*, while decreased *vacA* gene rates were reported in Ethiopia (90%) and Netherland (93%)²⁶. Regarding *vacA* gene subtypes Akeel et al.¹⁷ observed that the highly detected *vacA* subtypes were *s1as1bm2*, *m2* and *s1a1b* which detected in 23.4%, 16.4% and 16.4% of *H. pylori* isolates respectively. Similar results were found by Pajavand et al.²⁷ that the most detected *vacA* subtypes were *m2* (39.5). Moreover, Marie et al.¹¹ reported *vacA* alleles in Saudi cases as *vacAm2* (30%) and *s1a1b* (16%) in cases suffered from dyspepsia.

In the current work, no significant statistical difference was noticed among the *cagA*, *vacA* and *iceA* presence and gender. Although, *m2* subtype of *vacA* was increased in females, 63.64% than males 36.36%, while among males *m1*, it was 100% and *m2* was 63.64%. Kadi et al.¹⁴ also observed no sex variations associated with *cagA* and *iceA* genes distribution, while they reported that some *vacA* genotypes observed in female gender as *vacA m2* subtype in percentage of 65%, while it was 35% among men. Similar to Like these findings, El Khadir et al.²⁶ reported that *vacAm2* was more in women than in men.

Our work showed no observed significant differences between *vacA*, *cagA* and *iceA* and various groups of age. However, *m2* was high (54.55%) in the patients aged from 18 to 29 years, while it was decreased 1(9.09%) among patients aged from 30 to 49 years. and 3(27.27%) in patients aged more than 50 years old. Akeel et al.¹⁷ also reported that *vacAm2* subtype was more prevalent (62%) in young patients aged from 13 to 29 years, but in older patients, this gene prevalence was decreased (about 24 and 14 % in the patients aged between 30 and 49 years and more than 50 years, respectively). Also similar results were mentioned by Feliciano et al.²⁸.

In the present work a significant association (*p* value, 0.001) between the endoscopic features and *vacA* gene presence. The subtypes of *vacA*: *s2*, *m2*, *s1a1b*, *s1as1bm2*, were related to gastritis, while, *s1a*, *s1b*, *m1* subtypes were related to duodenal and gastric ulcers. These results matched with Pajavand et al.²⁷ and Sallas et al.²⁹ who reported association between *s2* and *m2* with gastritis and association between *s1* and *m1* with gastric ulcer. A research in Saudi Arabia conducted by Bibi et al.³⁰ revealed increased prevalence of *vacA s1* in patients who suffered from gastric ulcer (80%) or cancer (100%). Many researches were done in Western countries, Africa, China and Middle East, which reported that patients who harbored *vacA s1* or *m1* in *H.*

pylori strains had more risk for development of peptic ulcer and gastric cancer if compared with patients who had *s2* or *m2* *H. pylori* isolates. According to these findings *vacA s2* and *m2* isolates appeared to be less virulent than *s1a*, *s1b*, *m1* strains³¹

In this study no statistical significance (*p* value of 0.229) was detected between genotypes of *vacA* and histopathological alterations, although, *vacA* subtypes: *s2*, *s1a1b*, *s1as1bm2* were increased in sever chronic active gastritis. Akeel et al.¹⁷ also reported an increased rate of *vacA s1a1b* (16%). This finding matched also with the research of Sedaghat et al.²⁵ who reported increased rates of *s2*, *s1a*, *s1as1bm2* in relation to severe chronic active gastritis. It is known that chronic active gastritis may proceed to gastric metaplasia, dysplasia that could progress into gastric cancer³². The subtype *vacAS1a,S1b* and was related mainly to sever gastritis, while the subtype *vacA, m2 and S1as1bm2* was related to moderate active gastritis. The association between *vacA s1/m1* and serious gastric epithelium damage has been previously documented³³. Many studies revealed that *vacAs1, m1* rates between 24–84%²⁶.

In the current study no statistically significant differences were detected between *cagA* presence and endoscopic or histopathological reports, but more than 66% of duodenal ulcers had been related to positive *cagA*. Similar to these results, Seriki et al.³⁴ revealed that no relationship was found between the presence of *cagA* genes and clinical implications. Kadi et al.¹⁴ revealed also no statistically significant association between *cagA* presence and histological abnormalities. Momenah et al.²³ revealed the presence of association between peptic ulcers and *cagA* (100%) and Marie et al.¹¹ reported correlation between peptic ulcers and *cagA* (71%).

In our study, a significant association was found between *iceA1* and *iceA2* genes presence with gastritis and gastric ulcer as *p* value was 0.027 and also there was correlation between *iceA1* and *iceA2* with chronic active gastritis, 40% and 45% respectively, while the association between *iceA* negative cases with chronic active gastritis was (15%) only. Several studies^{14,23,24} agreed with association of *iceA1* presence with gastric ulcer and gastritis, while previous studies from Iran and Brazil revealed no relation between *iceA1* gene presence and gastritis^{25,35}

CONCLUSIONS

The current work reported an increased *H. pylori* prevalence rate which was about 67% in dyspeptic patients in Al Quwayiyah General Hospital, Saudi Arabia. There was a statistically significant association between *iceA1* and *iceA2* genotypes presence with gastric ulcer and gastritis. The identification of virulence factors of *H. pylori* allows the clinician to

identify high-risk patients associated with *H. pylori* infections.

Acknowledgements

The authors wish to express their gratitude to the staff of the Microbiology Laboratory of Al Quwayiyah General Hospital for their cooperation during study. This manuscript has not been previously published and is not under consideration in the same or substantially similar form in any other reviewed media. I have contributed sufficiently to the project to be included as author. To the best of my knowledge, no conflict of interest, financial or others exist. All authors have participated in the concept and design, analysis, and interpretation of data, drafting and revising of the manuscript, and that they have approved the manuscript as submitted

Ethical approval: Ethical approval was obtained from institutional ethics Committee of Al-Quwayiyh General Hospital.

REFERENCES

- McGee D. J. and Mobley H. L. T., "Pathogenesis of *Helicobacter pylori* infection," *Current Opinion in Gastroenterology*, 2000; 16(1):24–31
- Maeda S. and Mentis A. F., "Pathogenesis of *Helicobacter pylori* infection" *Helicobacter*. 2007; 12(1):10–14.
- Axon.A, "Helicobacter pylori and public health," *Helicobacter*. 2014; 19 (1): 68–73.
- Testerman T. L. and Morris J, "Beyond the stomach: an updated view of *Helicobacter pylori* pathogenesis, diagnosis, and treatment," *World Journal of Gastroenterology*, 2014; 20(36): 12781–12808.
- Kayali S, Aloe R, Bonaguri C, Gaiani F, Manfredi M, Leandro G, et al. Non-invasive tests for the diagnosis of *Helicobacter pylori*: state of the art. *Acta Biomed*. 2018; 89(8-S):58–64.
- Mégraud F. Advantages and disadvantages of current diagnostic tests for the detection of *Helicobacter pylori*. *Scand J Gastroenterol* 1996;31:57-62.
- Fasciana, T. Scarpulla, G. Giammanco A. et al., "Resistance to clarithromycin and genotypes in *Helicobacter pylori* strains isolated in Sicily," *Journal of Medical Microbiology*. 2015, 64 (11) ; 1408–1414.
- Fasciana T., Capra G., CalaC. et al., "Helicobacter pylori and epstein-barr co-infection in gastric disease," *Pharmacology online*, 2017;1: 73–82, .
- Leonardi M, La Marca G, Pajola B, Perandin F, Ligozzi M, Pomari E. Assessment of real-time PCR for *Helicobacter pylori* DNA detection in stool with co-infection of intestinal parasites: a comparative study of DNA extraction methods. *BMC Microbiol*. 2020; 20(1):131.
- Siddique I, Al-Qabandi A, Al-Ali J, Alazmi W, Memon A, , Mustafa AS, et al. Association between *Helicobacter pylori* genotypes and severity of chronic gastritis, peptic ulcer disease and gastric mucosal interleukin-8 levels: evidence from a study in the Middle East. *Gut Pathog* 2014;6: 41.
- Marie MA. Relationship between *Helicobacter pylori* virulence genes and clinical outcomes in Saudi patients. *J Korean Med Sci*. 2012;27:190–3.
- da Costa DM, dos Santos PE, Rabenhorst SH. What exists beyond *cagA* and *vacA*? *Helicobacter pylori* genes in gastric diseases. *World J Gastroenterol*. 2015;21:10563–72.
- Momtaz H, Souod N, Dabiri H, Sarshar M. Study of *Helicobacter pylori* genotype status in saliva, dental plaques, stool and gastric biopsy samples. *World J Gastroenterol*. 2012;18:2105–11.
- Kadi RH, Halawani EM, Abdelkader HS. Prevalence of *H. pylori* strains harbouring *cagA* and *iceA* virulence genes in Saudi patients with gastritis and peptic ulcer disease. *Microbiol Discov*. 2014;2:2
- Gray SF, Wyatt JI, Rathbone BJ. Simplified techniques for identifying *Helicobacter pylori* dis. *J Clin Pathol*. 1986;39:1279.
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. *Am J SurgPathol*. 1996;20: 1161–81.
- Akeel M , Shehata A, Elhafey A, Elmakki E, Aboshouk T, Ageely H and Mahfouz M *Helicobacter pylori vacA, cagA and iceA* genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical outcomes and histopathological changes. *BMC Gastroenterology*. 2019; 19:16
- Havaei A. P. Mohajeri, R. Khashei, R. Salehi, H. Tavakoli Prevalence of *Helicobacter Pylori vacA* different genotypes in Isfahan *Adv Biomed Res*. 2014;34:210-19
- Alanazi FH, Albriek AZ, et al. The prevalence of *Helicobacter pylori* infection in patients with dyspepsia in the central rural region of Saudi Arabia. *Indo Am J P Sci* 2019; 6:1358-1364.
- Ramis IB, Vianna JS, Silva LV, Junior, Von Groll A, Silva PE. *CagE* as a biomarker of the

- pathogenicity of *Helicobacter pylori*. *Rev Soc Bras Med Trop.* 2013;46(2):185–9.
21. AlEid A, Al Balkhi A, Hummedi A, Alshaya A, Abukhater M, Al Mtawa A, Al Khathlan A, Qutub A, Al Sayari K, Ahmad S, Azhar T, Al Otaibi N, Al Ghamdi A, Al Lehibi A. The utility of esophago-gastro-duoden-oscropy and *Helicobacter pylori* screening in the preoperative assessment of patients undergoing bariatric surgery: A cross-sectional, single-center study in Saudi Arabia. *Saudi J Gastroenterol.* 2020 ;26(1):32-38.
 22. Kao C, Sheu B, Wu J, et al. *Helicobacter pylori* infection: an overview of bacterial virulence factors and pathogenesis. *Biomed. J.* 2016; 39:14–23.
 23. Momenah AM, Tayeb MT. *Helicobacter pylori cagA* and *iceA* genotypes status and risk of peptic ulcer in Saudi patients. *Saudi Med J.* 2007; 28(3):382–5.
 24. Abu-Taleb AMF, Abdelattef RS, Abdel-Hady AA, et al. Prevalence of *Helicobacter pylori cagA* and *iceA* genes and their association with gastrointestinal diseases. *Int J Microbiol.* 2018;2018:4809093.
 25. Sedaghat H, Moniri R, Jamali R, et al. Prevalence of *Helicobacter pylori vacA, cagA, cagE, iceA, babA2*, and *oipA* genotypes in patients with upper gastrointestinal diseases. *Iran J Microbiol.* 2014; 6(1):14–21.
 26. El Khadir M, AlaouiBoukhris S, Benajah D-A, El Rhazi K, Ibrahim SA, El Abkari M, et al. *VacA* and *CagA* status as biomarker of two opposite end outcomes of *Helicobacter pylori* infection (gastric Cancer and duodenal ulcer) in a Moroccan population. *PLoS One.* 2017; 12:e0170616.
 27. Pajavand H, Alvandi A, Mohajeri P, et al. High frequency of *vacA* s1m2 genotypes among *Helicobacter pylori* isolates from patients with gastroduodenal disorders in Kermanshah, Iran. *Jundishapur J Microbiol.* 2015;8(11):e25425
 28. Feliciano O, Gutierrez O, Valdés L, Fragoso T, Calderin AM, Valdes AE, et al. Prevalence of *Helicobacter pylori vacA, cagA, and iceA* genotypes in Cuban patients with upper gastrointestinal diseases. *Biomed Res Int.* 2015; 753-61
 29. Sallas M, Melchiades J, Zabaglia L, Moreno J, et al. Prevalence of *Helicobacter pylori vacA, cagA, dupA* and *oipA* genotypes in patients with Gastric Disease. *Adv Mircobiol.* 2017; 7(1):1–9
 30. Bibi F, Alvi SA, Sawan SA, Yasir M, Sawan A, Jiman-Fatani AA, et al. Detection and genotyping of *Helicobacter pylori* among gastric ulcer and cancer patients from Saudi Arabia. *Pak J Med Sci.* 2017; 33:320–4
 31. Mendoza-Cantú A, Urrutia-Baca V, Urbina-Ríos C, De la Garza-Ramos M. et al. Prevalence of *Helicobacter pylori vacA* Genotypes and *cagA* Gene in Dental Plaque of Asymptomatic Mexican Children. *BioMed Res Int.* 2017. Article ID 4923640, 10 pages.
 32. Pinto-Ribeiro I, Ferreira RM, Batalha S, Hlaing T, Wong SI, Carneiro F, et al. *Helicobacter pylori vacA* Genotypes in Chronic Gastritis and Gastric Carcinoma Patients from Macau, China. *Toxins (Basel).* 2016; 8:142
 33. Hussein NR, Napaki SM, Atherton JC. A study of *Helicobacter pylori* associated gastritis patterns in Iraq and their association with strain virulence. *Saudi J Gastroenterol.* 2009; 15:125–7.
 34. Seriki AT, Smith SI, Adeleye AI, Fowora MA, Lesi O, et al. *Helicobacter pylori* cytotoxin-associated gene a protein among adult dyspeptic patients in South-Western Nigeria. *Afr J Microbiol Res.* 2017; 11:681–6
 35. Gatti LL, Módena JL, Payão SL, Smith MD, Fukuhara Y, Módena JL, et al. Prevalence of *Helicobacter pylori cagA, iceA* and *babA2* alleles in Brazilian patients with upper gastrointestinal diseases. *Acta Trop.* 2006; 100:232–40.